Posted On

The UCLA Institutional Biosafety Committee (IBC) would like to announce the transition of Human Gene Transfer (HGT) reviews to Western IRB’s Institutional Biosafety Committee Services (IBCS).

WIRB will provide primary review of New, Renewed, and Amended HGT submissions to the IBC. Review will include a risk assessment of materials and procedures as well as a review of documents, including Appendix M, Informed Consent, Investigator’s Brochure, FDA correspondence, NIH correspondence, SOPs and other relevant materials. WIRB will also confirm completion of proper training, inspections (as needed), applicable medical consults and exposure control plans. They will then present their approval recommendations at regularly scheduled IBC meetings. WIRB will bill study sponsors directly for these services so there will be no cost to researchers.

We believe this will be a seamless transition and look forward to WIRB’s expertise and experience with HGT reviews. More information about WIRB and IBCS is available at https://www.wirb.com/Pages/IBCServices.aspx.

If you have any questions or concerns, please feel free to contact our office.